Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Sesques

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Journal of Hematology & Oncology|July 3, 2026
Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control armGuillaume Cartron, Isabelle Chaillol, Roch Houot, et al.
Bone Marrow Transplantation|March 2, 2026
Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?Marta Canelo-Vilaseca, Mohamad Sabbah, Caterina Cristinelli, et al.
Blood|June 24, 2021
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphomaKai Rejeski, Ariel Perez, Pierre Sesques, et al.
Bone Marrow Transplantation|January 8, 2026
Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?Marta Canelo-Vilaseca, Mohamad Sabbah, Caterina Cristinelli, et al.
Clinical Nuclear Medicine|June 11, 2021
Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T CellsPierre Sesques, Jérémie Tordo, Emmanuelle Ferrant, et al.
Hematological Oncology|July 12, 2025
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell LymphomaJuliette Penichoux, Pierre Decazes, Cédric Rossi, et al.
Hemasphere|February 19, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registryJean Galtier, Charles Mesguich, Pierre Sesques, et al.
Blood Advances|October 20, 2023
High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphomaVincent Camus, Pierre-Julien Viailly, Fanny Drieux, et al.
American Journal of Hematology|December 11, 2020
First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French studyMarie-Charlotte Laude, Laure Lebras, Pierre Sesques, et al.
Blood Advances|August 30, 2021
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA studyVincent Camus, Cédric Rossi, Pierre Sesques, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Journal of Hematology & Oncology|July 3, 2026
Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control armGuillaume Cartron, Isabelle Chaillol, Roch Houot, et al.
Bone Marrow Transplantation|March 2, 2026
Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?Marta Canelo-Vilaseca, Mohamad Sabbah, Caterina Cristinelli, et al.
Blood|June 24, 2021
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphomaKai Rejeski, Ariel Perez, Pierre Sesques, et al.
Bone Marrow Transplantation|January 8, 2026
Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?Marta Canelo-Vilaseca, Mohamad Sabbah, Caterina Cristinelli, et al.
Clinical Nuclear Medicine|June 11, 2021
Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T CellsPierre Sesques, Jérémie Tordo, Emmanuelle Ferrant, et al.
Hematological Oncology|July 12, 2025
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell LymphomaJuliette Penichoux, Pierre Decazes, Cédric Rossi, et al.
Hemasphere|February 19, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registryJean Galtier, Charles Mesguich, Pierre Sesques, et al.
Blood Advances|October 20, 2023
High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphomaVincent Camus, Pierre-Julien Viailly, Fanny Drieux, et al.
American Journal of Hematology|December 11, 2020
First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French studyMarie-Charlotte Laude, Laure Lebras, Pierre Sesques, et al.
Blood Advances|August 30, 2021
Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA studyVincent Camus, Cédric Rossi, Pierre Sesques, et al.
Pageof 7